Sumitomo Mitsui Trust Group Inc. grew its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 0.7% during the 4th quarter, according to its most recent 13F filing with the Securities & ...

Fintel reports that on February 13, 2025, UBS upgraded their outlook for AstraZeneca PLC - Depositary Receipt () ...

Before taking its repurposed diabetes drug candidate into a phase 2 lupus trial, Conduit Pharmaceuticals is tapping Charles River Laboratories to help test the asset in a preclinical model of the ...

Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in previously untreated mantle cell lymphoma.

The Telegraph has been shortlisted for 18 honours at this year’s Press Awards, including daily and Sunday newspapers of the year ...

Barclays analyst Duffy Fischer upgraded DuPont de Nemours, Inc. DD from Underweight to Equal-Weight and boosted the price ...

UBS upgraded AstraZeneca (AZN) to Buy from Neutral with a price target of 14,200 GBp, up from 11,500 GBp. The firm cites the company’s ...

Stephens Inc. AR lessened its position in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 5.2% in the fourth quarter, Holdings Channel reports. The fund owned 24,987 shares of the company’s ...

AstraZeneca (NASDAQ:AZN) stock received a positive assessment from UBS, as analyst Matthew Weston upgraded the pharmaceutical giant's rating from Neutral to Buy. The upgrade was accompanied by a ...

AstraZeneca is expecting Phase III trial data for seven new medicines in 2025, its CEO said as he confirmed the company’s ...

Artificial intelligence (AI) can greatly help in this direction, as evidenced by a partnership between the pharmaceutical giant AstraZeneca and Qure.ai. Through its AI-powered tool, qXR, this ...

The discovery has shed light on a complex blood interaction that has likely always been present in humans but was unnoticed ...